Display triple medication combination lung deposition in an inhalation suspension: Glenmark is informed by the CDSCO Panel regarding pulmonary FDC drugs.

Published Date: 03 Nov 2023

New Delhi: In keeping with the bioequivalency (BE) and Phase III clinical trial proposal made by pharmaceutical giant Glenmark Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Q&A: When will individuals be able to receive customized cancer vaccines?

2.

Canadian Group Calls for Earlier Colorectal Cancer Screening

3.

Children living near oil and gas wells face higher risk of rare leukemia, studies show

4.

Researchers achieve a significant milestone in the management of anemia in chronic lymphocytic leukemia.

5.

Talquetamab Combos Show Survival Benefit in r/r Myeloma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot